Patents Issued in January 12, 2016
-
Patent number: 9233142Abstract: (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.Type: GrantFiled: June 2, 2014Date of Patent: January 12, 2016Assignees: National Hospital Organization Kinki-chuo Chest Medical center, AZBIO CorporationInventors: Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
-
Patent number: 9233143Abstract: Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.Type: GrantFiled: August 17, 2012Date of Patent: January 12, 2016Assignees: National Cerebral and Cardiovascular Center, Osaka University, Shionogi & Co., Ltd.Inventors: Kenji Kangawa, Hiroshi Hosoda, Takashi Nojiri, Meinoshin Okumura, Mayumi Furuya
-
Patent number: 9233144Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.Type: GrantFiled: September 18, 2009Date of Patent: January 12, 2016Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNEInventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
-
Patent number: 9233145Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.Type: GrantFiled: March 11, 2013Date of Patent: January 12, 2016Assignee: Biogen Hemophila Inc.Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
-
Patent number: 9233146Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.Type: GrantFiled: September 23, 2014Date of Patent: January 12, 2016Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 9233147Abstract: A first set of carbon nanotubes is functionalized with streptavidin and co-functionalized with a cell treatment payload material. A second set of carbon nanotubes is functionalized with biotin and co-functionalized with specific cell targeting material. Mixing the first and second sets causes four carbon nanotubes from the second set to attach to each carbon nanotube from the first set. Multiple replicated virus-like particles result. The pharmaceutical composition seeks out and attaches to target cells. The carbon nanotubes from the first set penetrate the targeted cells and deliver their cell treatment payloads into the targeted cells. Near infrared energy is transmitted through tissue heating the carbon nanotubes for targeted cell treatment.Type: GrantFiled: April 16, 2010Date of Patent: January 12, 2016Assignee: Oceanit Laboratories, Inc.Inventor: Thomas Alan Hasling
-
Patent number: 9233148Abstract: The present invention provides methods of differentiating the infectivity and lethality of isolates of influenza virus and provides compounds for diagnosing, preventing, and treating outbreaks of influenza virus including compounds for diagnosing, preventing, and treating across different strains of influenza virus.Type: GrantFiled: October 16, 2009Date of Patent: January 12, 2016Inventors: Samuel Bogoch, Elenore S. Bogoch, Anne Elenore Borsanyi, Samuel Winston Bogoch
-
Patent number: 9233149Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.Type: GrantFiled: September 16, 2013Date of Patent: January 12, 2016Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
-
Patent number: 9233150Abstract: The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides.Type: GrantFiled: April 11, 2012Date of Patent: January 12, 2016Assignee: Absynth Biologics LimitedInventors: Jorge Garcia Lara, Simon Foster
-
Patent number: 9233151Abstract: A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.Type: GrantFiled: April 4, 2012Date of Patent: January 12, 2016Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Dominique Boutriau, Carine Capiau, Pierre Michel Desmons, Dominique Lemoine, Jan Poolman
-
Patent number: 9233152Abstract: The present invention relates to murine monoclonal antibodies C, F and H which target major neutralizing epitopes of influenza H5 hemagglutinin of clade 2.3 and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using murine monoclonal antibodies C, F or H or active fragments thereof. The present invention additionally relates to methods and compositions for providing universal protection against H5 influenza viruses using murine monoclonal antibodies C, F or H or fragments thereof together with complementary murine monoclonal antibody or active fragments thereof. The present invention further relates to methods and compositions for the characterization and quantification of H5 expression using these murine monoclonal antibody or fragments thereof.Type: GrantFiled: January 12, 2012Date of Patent: January 12, 2016Assignee: Temasek Life Sciences Laboratory LimitedInventors: Fang He, Jimmy Hwei-Sing Kwang
-
Patent number: 9233153Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: GrantFiled: October 5, 2012Date of Patent: January 12, 2016Assignee: GenVec, Inc.Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
-
Patent number: 9233154Abstract: The present invention relates to compositions and methods for the modulation of TH17 responses. The invention provides compositions for the induction of TH17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing TH17 responses. In other embodiments, the invention provides compositions for the inhibition of TH17 responses containing one or more blocking agents. Methods and compositions for the modulation of TH17 responses and for the treatment of TH17-associated diseases and for cancer are also provided.Type: GrantFiled: December 13, 2013Date of Patent: January 12, 2016Assignee: Icahn School of Medicine at Mount SinaiInventors: Julie Magarian Blander, Miriam Torchinsky
-
Patent number: 9233155Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.Type: GrantFiled: April 1, 2014Date of Patent: January 12, 2016Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Bo Gyou Kim, Ji Min Lee, Kyung Ah Kim, Yun Ju Jeong
-
Patent number: 9233156Abstract: The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.Type: GrantFiled: May 2, 2012Date of Patent: January 12, 2016Assignee: IMMUNOVATIVE THERAPIES LTD.Inventor: Michael Har-Noy
-
Patent number: 9233157Abstract: A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.Type: GrantFiled: November 26, 2014Date of Patent: January 12, 2016Inventor: Gholam A. Peyman
-
Patent number: 9233158Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: GrantFiled: May 20, 2015Date of Patent: January 12, 2016Assignee: Pulmatrix, Inc.Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Patent number: 9233159Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.Type: GrantFiled: October 24, 2012Date of Patent: January 12, 2016Assignees: MannKind Corporation, Torrey Pines Institute for Molecular StudiesInventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
-
Patent number: 9233160Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: GrantFiled: December 17, 2014Date of Patent: January 12, 2016Assignee: DURECT CORPORATIONInventors: Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton, Roger Fu, Michael S. Zamloot
-
Patent number: 9233161Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.Type: GrantFiled: February 10, 2013Date of Patent: January 12, 2016Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9233162Abstract: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function.Type: GrantFiled: November 19, 2010Date of Patent: January 12, 2016Assignee: The Board of Regents of the University of Texas SystemInventors: Thomas Kodadek, D. Gomika Udugamasooriya, Rolf Brekken
-
Patent number: 9233163Abstract: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.Type: GrantFiled: December 28, 2011Date of Patent: January 12, 2016Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Robert J. Levy
-
Patent number: 9233164Abstract: The present invention provides water soluble fullerene formulations and methods of use thereof.Type: GrantFiled: January 13, 2012Date of Patent: January 12, 2016Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Alexander V. Kabanov, Jing Tong
-
Patent number: 9233165Abstract: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.Type: GrantFiled: April 13, 2009Date of Patent: January 12, 2016Assignee: NEKTAR THERAPEUTICSInventors: Jennifer Riggs-Sauthier, Franco J. Duarte
-
Patent number: 9233166Abstract: Disclosed are nanoparticles, such as carbon nanotubes or other graphitic sheet materials having extended aromatic surfaces, which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer or adsorption of an amphiphilic molecule to render them stable in suspension. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e.g., in tumor cells. The drug may also be linked to a branched chain hydrophilic polymer, so that each polymer molecule carries more than one drug bound by a cleavable linker.Type: GrantFiled: September 16, 2013Date of Patent: January 12, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Hongjie Dai, Zhuang Liu, Xiaolin Li, Xiaoming Sun
-
Patent number: 9233167Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.Type: GrantFiled: December 23, 2014Date of Patent: January 12, 2016Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
-
Patent number: 9233168Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.Type: GrantFiled: December 23, 2014Date of Patent: January 12, 2016Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
-
Patent number: 9233169Abstract: The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.Type: GrantFiled: February 20, 2015Date of Patent: January 12, 2016Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
-
Patent number: 9233170Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.Type: GrantFiled: January 17, 2014Date of Patent: January 12, 2016Assignee: Arrowhead Research CorporationInventor: Jon E. Chatterton
-
Patent number: 9233171Abstract: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.Type: GrantFiled: November 21, 2012Date of Patent: January 12, 2016Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Peter U. Park, Thomas Chittenden
-
Patent number: 9233172Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: GrantFiled: March 17, 2015Date of Patent: January 12, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Patent number: 9233173Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: GrantFiled: April 8, 2010Date of Patent: January 12, 2016Assignees: Deutsches Krebsforschungszentrum, Heinz FaulstichInventors: Heinz Faulstich, Gerhard Moldenhauer, Werner Simon, Jan Anderl, Christoph Müller
-
Patent number: 9233174Abstract: The present invention provides minicircle nucleic acid vector formulations for use in administering to a subject, wherein the minicircle nucleic acid vectors include a polynucleotide of interest, a product hybrid sequence of a unidirectional site-specific recombinase, and are devoid of plasmid backbone bacterial DNA sequences. Also provided are methods of producing the subject formulations as well as methods for administering the minicircle nucleic acid vector formulations to a subject. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications.Type: GrantFiled: February 2, 2015Date of Patent: January 12, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Zhi-Ying Chen, Mark A. Kay
-
Patent number: 9233175Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods of imaging of inflammatory diseases using the compounds.Type: GrantFiled: December 19, 2013Date of Patent: January 12, 2016Assignee: Purdue Research FoundationInventors: Philip S. Low, Sumith A. Kularatne, Lindsay E. Kelderhouse, Sakkarapalayam M. Mahalingam
-
Patent number: 9233176Abstract: A method for injection of an imaging contrast into a patient, includes: a. in a first phase, injecting a fluid having a first concentration of contrast agent for a first period of time; and b. in a second phase, injecting a fluid having a second concentration of contrast agent for a second period of time. The osmolarity of the second phase is higher than the osmolarity of the first phase. The method can further include: c. in a third phase, subsequent to the second phase, injecting a fluid having a third concentration of contrast agent for a third period of time. The osmolarity of the third phase is lower than the osmolarity of the second phase. In embodiments in which the composition of the contrast agent of the third phase is the same as the composition of the contrast agent of the second phase, the third concentration can be lower than the second concentration.Type: GrantFiled: June 6, 2007Date of Patent: January 12, 2016Assignee: Bayer HealthCare LLCInventors: Ruediger Lawaczek, John F. Kalafut
-
Patent number: 9233177Abstract: Endohedral metallofullerene compounds, which in water has a relaxivity of about 30 mM?1 S?1 to about 300 mM?1 S?1 and forms a dispersion in water with entities having an average hydrodynamic radius of less than about 20 nm.Type: GrantFiled: October 22, 2008Date of Patent: January 12, 2016Assignee: Luna Innovations IncorporatedInventors: Darren K. Macfarland, Robert P. Lenk, Rajesh Shukla, Kenneth L. Walker, Stephen R. Wilson, Zhiguo Zhou
-
Patent number: 9233178Abstract: Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.Type: GrantFiled: July 14, 2014Date of Patent: January 12, 2016Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Martin G. Pomper, Haofan Wang, Tomas R. Guilarte
-
Patent number: 9233179Abstract: A sanitizing system for use with monitors, particularly including touchscreen monitors, includes an ultraviolet light source positioned about a periphery of the monitor and configured to transmit light toward the monitor. A sensor detects the presence of an object such as a human finger in the close vicinity or in contact with the monitor in order to stop the operation of the lights.Type: GrantFiled: October 1, 2014Date of Patent: January 12, 2016Assignee: VIOGUARD LLCInventors: Craig Ranta, Steven Swedenberg
-
Patent number: 9233180Abstract: An aqueous disinfecting solution, a concentrated version of the solution, and a dry powdered composition which may be dissolved in water to provide the solution. The solution has a pH of from 0.6 to 7 and comprises (a) hydrogen peroxide in a concentration of from 0.01 to 6% w/w; and (b) at least one component chosen from cyclic carboxylic acids and aromatic alcohols, in a concentration of from 0.01 to 10% w/w, all based on the total weight of the solution. The cyclic carboxylic acids are preferably 2-furan carboxylic acid, benzoic acid and salicylic acid and the aromatic alcohol is preferably benzyl alcohol. Furthermore, the solution may contain surfactants, corrosion inhibitors, hydrotropes, cation sequestering agents, hydrogen peroxide stabilizers, solvents, thickeners, skin conditioning agents, antifoams, and pH buffers.Type: GrantFiled: October 17, 2013Date of Patent: January 12, 2016Assignee: VIROX TECHNOLOGIES INC.Inventors: Navid Omidbakhsh, Jose A. Ramirez
-
Patent number: 9233181Abstract: Endoscope connection portions, a fluid feeding duct, a liquid supply duct, a pump, a first atmospheric exposure duct including one end connected to the fluid feeding duct and the other end exposed to atmosphere, a relief valve disposed at an intermediate position of the first atmospheric exposure duct, a first stop section disposed at an intermediate position of the first atmospheric exposure duct, and a control section that performs control to supply a liquid to ducts of endoscopes and controls at least opening/closing operation of the first stop section are included.Type: GrantFiled: January 16, 2015Date of Patent: January 12, 2016Assignee: OLYMPUS CORPORATIONInventors: Takaaki Komiya, Jiro Komiya
-
Patent number: 9233182Abstract: A mobile disinfection unit for use in a method of disinfecting a given facility or equipment such as a room, apparatus, container or vehicle. The unit includes a catalytic converter device for decomposing ozone, a VOC filter for removing bacterial viruses and other contaminants and an electrostatic filter for removing molecules, particles, droplets, smoke and dust. The method includes a treatment step for adding ozone and steam/water droplets into the air of the facility or equipment, a detection step of continuously detecting the ozone concentration in the facility or equipment, and a removal step arranged for removing residual ozone and any contaminates from the facility or equipment when a predefined ozone concentration has been reached and maintained for a specific time interval.Type: GrantFiled: January 25, 2013Date of Patent: January 12, 2016Assignee: O3 Technology Research & Development ABInventor: Jan Arlemark
-
Patent number: 9233183Abstract: The present invention relates to a device for indoor air purification and sterilization which excites indoor air by arc discharge to decompose bad odor and sterilize air, wherein an excited state is maintained by applying a magnetic field and the contact time between molecules activated by arc and pollutants is extended, thereby improving air purification and sterilization effects, and the noise generated by arc discharge is reduced by a silencer and ozone and static electricity are removed by a filter which removes ozone and a metal filter for removing static electricity, respectively, thereby enabling very suitable configuration for indoor air purification and sterilization.Type: GrantFiled: October 11, 2010Date of Patent: January 12, 2016Inventor: Bu-yeol Kim
-
Patent number: 9233184Abstract: An adhesive preparation comprising a stretchable support and an adhesive layer laminated on at least one side of the support, wherein the stretchable support comprises a interlock woven fabric subjected to crimping processing, the adhesive layer contains 10% by mass or more of methyl salicylate with respect to the total mass of the layer, the whole adhesive preparation has moisture permeability of 1 to 350 g/m2·24 hr measured at a temperature of 40° C. and a relative humidity of 90%, and the methyl salicylate has a plasma AUC0-24 ranging from 3.0 to 60.0 ng·hr/mL in terms of a mean±standard deviation, and salicylic acid as a metabolite of the methyl salicylate has a plasma AUC0-24 ranging from 5000 to 13000 ng·hr/mL in terms of a mean±standard deviation, when the adhesive preparation is applied to a human skin for 8 hours such that an application amount of the adhesive layer applied is 50 to 300 g/m2 and a contact area is 280 cm2.Type: GrantFiled: July 8, 2014Date of Patent: January 12, 2016Assignee: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Kiyomi Tsuruda, Shinji Yamasoto, Kouki Shoho, Masaru Nakanishi
-
Patent number: 9233185Abstract: The purpose of the present disclosure is to provide an absorbent article that can be made smaller because the crown section continues to fit the wearer's excretory opening, which has a complex shape, both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood, and with which leakage does not occur easily. This absorbent article is as follows: The absorbent article (1), which comprises a liquid-permeable top sheet (4), a liquid-impermeable back sheet, and a specified absorbent (7) between the liquid permeable top sheet (4) and the liquid-impermeable back sheet, is characterized in that: the absorbent article (1) has a crown section (2), which protrudes in the thickness direction of the absorbent article (1) in the region that is in contact with the excretory opening and comprises a specified cushion section; and in the central section, the crown section (2) has a compression workload (WC) of 10-50 (N·m/m2) and a compression resilience (RC) of 35-100%.Type: GrantFiled: March 26, 2013Date of Patent: January 12, 2016Assignee: UNICHARM CORPORATIONInventors: Yuki Noda, Tatsuya Tamura, Akira Hashino
-
Patent number: 9233186Abstract: The disclosed process for producing a water-absorbing resin comprising: a polymerization step of polymerizing an aqueous unsaturated monomer; a drying step of drying a particulated water-containing gel-liked crosslinked polymer, obtained in a finely crushing step during the polymerization or after the polymerization; a pulverizing step after the drying, a classification step after the drying, and a surface treatment step after the classification. In the process is, the surface-treatment step is interrupted with a heating treatment apparatus kept in a heated state and thereafter the surface treatment step is restarted.Type: GrantFiled: March 14, 2011Date of Patent: January 12, 2016Assignee: NIPPON SHOKUBAI CO., LTD.Inventors: Syuji Kanzaki, Sumio Okuda, Kunihiko Ishizaki, Satoshi Matsumoto
-
Patent number: 9233187Abstract: The present invention relates to a biodegradable suture-type cell delivery system, a preparation method thereof and a biodegradable suture comprising the same. The biodegradable suture-type cell delivery system has improved cell compatibility as a result of depositing a hydrophilic functional group-containing compound on the surface of a biodegradable suture yarn made of a biodegradable polymer, a portion of which has partially a bulky structure beneficial for the proliferation of cells or living tissue, so as to hydrophilically modify the surface, and then bonding a cell compatible material to the surface, and also functions as a cell culture scaffold, because the bulky structure is beneficial for the proliferation of cells. Accordingly, the biodegradable suture-type cell delivery system can improve the rate of engraftment of stem cells in vivo.Type: GrantFiled: November 18, 2009Date of Patent: January 12, 2016Assignee: Catholic University Industry Academic Cooperation FoundationInventors: Heung Jae Chun, Su Jung You, Ki Dong Yoo, Kyu Nam Park, Gue Tae Chae, Seok Whan Moon, Han Joon Kim, Jung Hee Wee
-
Patent number: 9233188Abstract: The subject matter of the invention is a curable composition for use as bone cement, in particular for augmentation of osteoporotic bone tissue, comprising at least one organic polymer and at least one monomer for radical polymerization, at least one particulate inorganic additive having a BET surface of at least 40 m2/g, whereby the additive comprises covalently bound hydroxyl groups, whereby the composition further comprises at least one fatty acid ester or a mixture of fatty acid esters. Another subject matter of the invention is the use of said composition for augmentation of osteoporotic bone tissue and particularly preferably for vertebroplasty, kyphoplasty, and augmentation of drill holes in osteoporotic bone tissue, as well as a kit for producing said composition.Type: GrantFiled: November 13, 2013Date of Patent: January 12, 2016Assignee: HERAEUS MEDICAL GMBHInventor: Sebastian Vogt
-
Patent number: 9233189Abstract: The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 ?m and an augmentation fraction of ceramic particles of at least 20 ?m. The ceramics typically include calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions.Type: GrantFiled: November 26, 2012Date of Patent: January 12, 2016Assignee: Cam Bioceramics B.V.Inventors: Klaas De Groot, Nienke de Roode-Beuling, Nol Van De Mortel, Mariska Bezemer
-
Patent number: 9233190Abstract: A culture medium includes a carbon nanotube structure and a hydrophilic layer. The culture medium is capable of culturing at least one neuron. The hydrophilic layer has a polar surface and is located on a surface of the carbon nanotube structure. The polar surface is located on a surface of the hydrophilic layer away from the carbon nanotube structure, and has a polarity attracted to a polarity of the at least one neuron.Type: GrantFiled: January 13, 2012Date of Patent: January 12, 2016Assignees: Tsinghua University, HON HAI PRECISION INDUSTRY CO., LTD.Inventors: Chen Feng, Li Fan, Wen-Mei Zhao
-
Patent number: 9233191Abstract: The present invention is related to a medical device carrying at least on a portion of its surface at least one drug or drug preparation and at least one lipophilic lubricant at a ratio of 0.1-500% by weight of the at least one lubricant in relation to 100% by weight of the drug, wherein the at least one drug is selected of paclitaxel, arsenic trioxide, and lipophilic derivatives of corticoids and selected Limus drugs, and the at least one lipophilic lubricant is a C6-C30-monocarboxylic acid salt.Type: GrantFiled: December 14, 2012Date of Patent: January 12, 2016Assignee: InnoRa GmbHInventors: Madeleine Caroline Berg, Thomas Speck